MGH2 and Amplicon Viral Core

神经减弱型复制能力HSV-1突变体的临床研究 ICP6和扩增子载体一直受到无法持续生产载体种群的限制 足够的数量和质量。核心B的目标将是为项目调查人员提供MGH2 (Gamma-34.5/ICP6突变体)和扩增子病毒库都是高滴度和高纯度的，而 根据病媒特定的协议始终如一地产生DING。以这种方式生产的向量股票 将在构成DNA病毒批次释放标准的所有主要质量控制领域进行表征 供临床使用。这种方法将产生不会受到问题阻碍的临床前数据 用于临床前研究的载体种群与可能使用的载体种群之间的生物等效性 后来在临床环境中。使用高度纯化和特征化的载体种群也将使程序 研究人员更全面地了解载体的潜在功效和作用机制 在临床前环境中进行分娩，无需担心使用不均匀材料可能导致的虚假结果 被野生型病毒或高水平缺陷病毒污染的媒介股票或载体股票 颗粒、污染蛋白质或宿主细胞DNA。

The clinical study of neuro-attenuated replication competent HSV-1 mutants deleted for gamma-34.5 and ICP6 and amplicon vectors has been limited by the inability to consistently produce vector stocks in adequate quantity and quality. The goal of Core B will be to provide program investigators with MGH2 (gamma-34.5/ICP6 mutant) and amplicon viral stocks that are both high in titer and highly purified while Deing consistently produced according to vector specific protocols. Vector stocks produced in this manner will be characterized across all major quality control areas that make up lot release criteria of DNA viruses for clinical use. This approach will result in generation of pre-clinical data that will not be hampered by issues of bio-equivalency between vector stocks that are used for pre-clinical studies and those that may be used later in a clinical setting. The use of highly purified and characterized vector stocks will also allow program investigators to more completely understand the potential efficacy and mechanism of activity of vector delivery in the pre-clinical setting without the worry of spurious results that may result from the use of nonuniform vector stocks or vector stocks that are contaminated with wild type virus or high levels of defective particles, contaminating proteins, or host cell DNA.